*Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 2Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

Dow Jones · 2d ago

Please log in to view news